SEC Tracker
Get the app

Skye Bioscience SKYE

Skye Bioscience to merge with Redx Pharma

PRER14A filing

Form
PRER14A
Filed
Importance
Routine
  1. Skye to acquire Redx's share capital via scheme of arrangement
  2. Exchange ratio of 0.0892 for Scheme Shares
  3. Series A Financing of $36.0 million for Redx
  4. Concurrent Financing of $67.9 million for Skye

Written from the PRER14A on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Skye Bioscience files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Agenus AGEN public float $135M, Jun 30, 2025
  2. Vistagen Therapeutics VTGN public float $138M, Sep 30, 2025
  3. Kodiak Sciences KOD public float $122M, Jun 28, 2025
  4. Voyager Therapeutics VYGR public float $144M, Jun 30, 2025
  5. Eledon Pharmaceuticals ELDN public float $145M, Jun 30, 2025